A Study of LOXO-305 in Chinese Participants With Blood Cancer (Including Lymphoma and Chronic Leukemia)
Completed · Phase 2 · NCT04849416
Conditions: Leukemia, Lymphoid, Lymphoma, Non-Hodgkin, Lymphoma, Mantle-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Lymphoma, B-Cell, Marginal Zone, Leukemia, Lymphocytic, Chronic, B-Cell
At a glance
- Research payments reported, 2025
- $14,017
- U.S. investigators named
- 0
- Sites paid
- 0
- Planned or actual enrollment
- 87
About the trial
- Sponsor
- Eli Lilly and Company (with Loxo Oncology, Inc.)
- Tested
- LOXO-305 (drug)
- Dates
- Started 2021-05-14; completion 2025-12-29
- Results posted
- Yes
A study of the safety, side effects, and effectiveness of LOXO-305 in Chinese adults with lymphoma or chronic leukemia who have already had standard of care treatment. Participation could last up to four years.
From ClinicalTrials.gov, last updated 2026-02-06. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Eli Lilly and Company reported $14,017 in research payments for this study in 2025 (8 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
Sites paid to run it
- $14,017
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.